07 December 2022: Clinical Research
A Prospective Questionnaire-Based Study to Evaluate Factors Affecting the Decision to Receive COVID-19 Vaccination in 267 Patients with Inflammatory Bowel Disease in Poland
Michał Łodyga 12ABCDEF* , Katarzyna Maciejewska 1ABCDF , Grażyna Rydzewska 13ADFGDOI: 10.12659/MSM.938665
Med Sci Monit 2022; 28:e938665
Table 3 Group characteristics – history of IBD.
| Variable | Value, n (%) |
|---|---|
| Group | |
| Ulcerative colitis | 107 (40.1) |
| Crohn’s disease | 160 (59.9) |
| Duration of disease (years) | 11 (6; 15)* |
| Medication used | |
| Mesalamine | 203 (77.8) |
| Sulfasalazine | 21 (8.0) |
| Steroids | 62 (23.8) |
| Thiopurines | 142 (54.4) |
| Methotrexate, cyclosporine | 8 (3.1) |
| Infliximab, vedolizumab, adalimumab, ustekinumab | 157 (60.2) |
| Tofacitinib | 10 (3.8) |
| Other | 1 (0.4) |
| Surgical interventions | 91 (34.1) |
| Number of operations | 2.00 (1.00; 3.00)* |
| IBD – inflammatory bowel disease; * 95% Cl. | |